Study Stopped
Recruitment rate not reached.
Visual Telerehabilitation in AMD Patients
Visual Rehabilitation in Macular Degeneration: a Pilot Study on Biofeedback Training and Home-based Mobile Virtual-reality Stimulation
1 other identifier
interventional
16
1 country
1
Brief Summary
Following the degeneration of the macula and the loss of central vision, the patients naturally relocate the fixation point for high visual acuity peripherally, in an eccentric and healthy part of the retina (PRL), to compensate for visual impairments. However, in many cases, the PRL lands on a sub-optimal retinal area and becomes useless. Modern low-vision rehabilitation procedures for AMD patients include biofeedback training (BFT) to relocate the PRL to a healthy retinal patch and acquire better fixation skills. This study seeks to combine BFT with home-based immersive virtual-reality audiovisual stimulation and measure feasibility and potential effectiveness on oculomotor control and visual perception.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 15, 2020
CompletedFirst Posted
Study publicly available on registry
December 28, 2020
CompletedStudy Start
First participant enrolled
September 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 6, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 6, 2023
CompletedNovember 30, 2023
November 1, 2023
2.1 years
December 15, 2020
November 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Feasibility of home-based IVR audiovisual stimulation
Feasibility objectives for our pilot study to be considered successful: 1. Number of patients completing the stimulation protocol: ≥ 13 out of 16 patients (81%) per group. 2. Number of IVR sessions performed by the patients to consider the stimulation protocol complete: ≥ 13 sessions out of 16 (81%). 3. Number of consecutive virtual-reality induced symptoms and effects (VRISE) scores \< 25: ≤ 3 per patient during the treatment period. 4. Number of patient drop-outs due to cybersickness (discomfort symptoms experienced in VR): ≤ 3 (19%) during the treatment period. 5. Number of randomized patients per week: ≥ 3 patients.
18 months
Secondary Outcomes (6)
Visual Acuity
from baseline to end of follow-up at 7 months
Retinal Sensitivity
from baseline to end of follow-up at 7 months
Fixation stability
from baseline to end of follow-up at 7 months
Contrast Sensitivity
from baseline to end of follow-up at 7 months
Reading Speed
from baseline to end of follow-up at 7 months
- +1 more secondary outcomes
Study Arms (2)
Biofeedback Training
ACTIVE COMPARATOR* Biofeedback training (BFT): 1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks. 1 session per week for 4 weeks (4 sessions total). * 30 min daily reading at home for 4 weeks.
Biofeedback Training + Immersive VR
EXPERIMENTAL* Biofeedback training (BFT) \[1 sessions of 4 x 20 minutes blocks. Rest time of 5 minutes between blocks\], 1 session per week for 4 weeks (4 sessions total). * 30 min daily reading at home for 4 weeks * Immersive virtual-reality stimulation (IVR) \[1 session of 3 blocks of 15 trials of 20 seconds each. Rest time is 1-2 minute(s) between blocks\], 1 session every 2 days for 4 weeks (14 sessions total).
Interventions
Audiovisual stimulation
Eligibility Criteria
You may qualify if:
- Dry-AMD.
- BCVA \> 20/160.
- Ability to follow the visual and auditory stimuli and training instructions.
- Auditory test positive at 50Hz 25-60dBHL.
- Home Wi-Fi access.
You may not qualify if:
- Wet AMD.
- Both eyes with media opacity that impairs microperimetry testing.
- Inability to perform during testing and training.
- Psychoactive drugs consumption.
- History of vertigo or dizziness
- Prior vision rehabilitation interventions.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Michael Reberlead
Study Sites (1)
Krembil Research Institute/Toronto Western Hospital
Toronto, Ontario, M5T 0S8, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 15, 2020
First Posted
December 28, 2020
Study Start
September 15, 2021
Primary Completion
October 6, 2023
Study Completion
October 6, 2023
Last Updated
November 30, 2023
Record last verified: 2023-11